The efficacy of romiplostim in the treatment of severe thrombocytopenia associated to Evans syndrome refractory to rituximab

Lupus

Volumn 20, Issue 12, 2011, Pages 1321-1323

  Gonzalez Nieto, J A ^a   Martin Suarez, I ^a   Quattrino, S ^a   Ortiz Lopez, E ^a   Munoz Beamud F R ^a   Colchero Fernandez J ^a   Alcoucer Diaz, M R ^a  

^a Juan Ramon Jimenez Hospital   (Spain)

Author keywords

antiphospholipid syndrome; Evans syndrome; rituximab; romiplostim; systemic lupus erythematosus; thrombocytopenia

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; ROMIPLOSTIM;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CASE REPORT; DRUG EFFICACY; HUMAN; MALE; PRIORITY JOURNAL; SPLENECTOMY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIPHOSPHOLIPID SYNDROME; CYCLOPHOSPHAMIDE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PLATELET COUNT; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; SPLENECTOMY; THROMBOCYTOPENIA; THROMBOPOIETIN;

EID: 80053652493     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203311404913     Document Type: Article

References (17)

1. Evans RS, Takahashi K, Duane RT, Payne R, Liu C. Primary thrombocytopenic purpura and acquired haemolytic anemia; evidence for a common etiology. AMA Arch Intern Med. 1951 ; 87: 48-65
2. Norton A, Roberts I. Management of Evans syndrome. Br J Haematol. 2006 ; 132: 125-137 (Pubitemid 43381548)
3. Kotb R, Pinganaud C, Trichet C, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol. 2005 ; 75: 60-64 (Pubitemid 40873963)
4. Scaradavou A, Bussel J. Evans syndrome. Results of a pilot study utilizing a multiagent treatment protocol. J Pediatr Hematol Oncol. 1995 ; 17: 290-295
5. Williams JA, Boxer LA. Combination therapy for refractory idiopathic thrombocytopenic purpura in adolescents. J Pediatr Hematol Oncol. 2003 ; 25: 232-235 (Pubitemid 36292839)
6. Suarez IM, Diaz RA, Aguayo-Canela D, Pujol de la Llave E. Correction of severe thrombocytopenia with chloroquine in the primary antiphospholipid syndrome. Lupus. 1996 ; 5: 81-83 (Pubitemid 26072435)
7. Mantadakis E, Danilatou V, Stiakaki E, Kalmanti M. Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases. Am J Hematol. 2004 ; 77: 303-310 (Pubitemid 39430712)
8. Rückert A, Glimm H, Lübbert M, Grüllich C. Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up. Lupus. 2008 ; 17: 757-760
9. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP. N Engl J Med. 2006 ; 355: 1672-1681 (Pubitemid 44583957)
10. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004 ; 76: 628-638 (Pubitemid 39601552)
11. Newland A, Caulier MT, Kappers-Klunne M, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol. 2006 ; 135: 547-553 (Pubitemid 44583422)
12. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet. 2008 ; 371: 395-403 (Pubitemid 351181334)
13. George JN, Mathias SD, Go RS, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol. 2009 ; 144: 409-415
14. Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010 ; 28: 437-444
15. Perreault S, Burzynski J. Romiplostim: a novel thrombopoiesis-stimulating agent. Am J Health Syst Pharm. 2009 ; 66: 817-824
16. Frampton JE, Lyseng-Williamson KA. Romiplostim. Drugs. 2009 ; 69: 307-317
17. Jamali F, Lemery S, Ayalew K, et al. Romiplostim for the treatment of chronic immune (idiophatic) thrombocytopenic purpura. Oncology. 2009 ; 23: 704-709